Ubiquitin signaling in pancreatic ductal adenocarcinoma

被引:2
作者
Lv, Shengnan [1 ]
Zhang, Jian [1 ]
Peng, Xinyu [1 ]
Liu, Huan [1 ]
Liu, Yan [2 ]
Wei, Feng [1 ]
机构
[1] First Hosp Jilin Univ, Gen Surg Ctr, Dept Hepatobiliary & Pancreat Surg, Changchun, Jilin, Peoples R China
[2] Chinese Acad Agr Sci, Changchun Vet Res Inst, Key Lab Jilin Prov Zoonosis Prevent & Control, Changchun, Peoples R China
基金
中国国家自然科学基金;
关键词
pancreatic ductal adenocarcinoma; ubiquitination; ubiquitin-protein ligases; deubiquitinating enzymes; proteolysis-targeting chimeras; CANCER PROGRESSION; ACHIEVES SAFE; BETA-CATENIN; PROMOTES; GROWTH; PROTAC; CHEMORESISTANCE; EXPRESSION; PROTEINS; PROLIFERATION;
D O I
10.3389/fmolb.2023.1304639
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignant tumor of the digestive system, characterized by rapid progression and being prone to metastasis. Few effective treatment options are available for PDAC, and its 5-year survival rate is less than 9%. Many cell biological and signaling events are involved in the development of PDAC, among which protein post-translational modifications (PTMs), such as ubiquitination, play crucial roles. Catalyzed mostly by a three-enzyme cascade, ubiquitination induces changes in protein activity mainly by altering their stability in PDAC. Due to their role in substrate recognition, E3 ubiquitin ligases (E3s) dictate the outcome of the modification. Ubiquitination can be reversed by deubiquitylases (DUBs), which, in return, modified proteins to their native form. Dysregulation of E3s or DUBs that disrupt protein homeostasis is involved in PDAC. Moreover, the ubiquitination system has been exploited to develop therapeutic strategies, such as proteolysis-targeting chimeras (PROTACs). In this review, we summarize recent progress in our understanding of the role of ubiquitination in the development of PDAC and offer perspectives in the design of new therapies against this highly challenging disease.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Precision treatment of pancreatic ductal adenocarcinoma
    Wei, Hongyun
    Ren, He
    CANCER LETTERS, 2024, 585
  • [32] Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma
    Bose, Mukulika
    Grover, Priyanka
    Sanders, Alexa J.
    Zhou, Ru
    Ahmad, Mohammad
    Shwartz, Sophia
    Lala, Priyanka
    Nath, Sritama
    Yazdanifar, Mahboubeh
    Brouwer, Cory
    Mukherjee, Pinku
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [33] Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice
    Hedegger, Kathrin
    Alguel, Hana
    Lesina, Marina
    Blutke, Andreas
    Schmid, Roland M.
    Schneider, Marlon R.
    Dahlhoff, Maik
    MOLECULAR ONCOLOGY, 2020, 14 (08) : 1653 - 1669
  • [34] Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition
    Brannon, Arthur, III
    Drouillard, Donovan
    Steele, Nina
    Schoettle, Shadae
    Abel, Ethan V.
    Crawford, Howard C.
    Pasca di Magliano, Marina
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [35] ETV4 promotes pancreatic ductal adenocarcinoma metastasis through activation of the CXCL13/CXCR5 signaling axis
    Gao, Xiaoliang
    Jiang, Mingzuo
    Chu, Yi
    Han, Yuying
    Jin, Yirong
    Zhang, Wenyao
    Wang, Weijie
    Yang, Suzhen
    Li, Wenjiao
    Fan, Ahui
    Cao, Jiayi
    Wang, Jiayao
    Liu, Hao
    Fu, Xin
    Chen, Di
    Nie, Yongzhan
    Fan, Daiming
    CANCER LETTERS, 2022, 524 : 42 - 56
  • [36] Immunophenotypes of Ductal Epithelial Cells in Advanced Pancreatic Ductal Adenocarcinoma
    Zhou, Rui
    Xu, Xiaoxiao
    Liu, Meizhen
    Wu, Xinmou
    Li, Rong
    DIGESTION, 2019, 99 (03) : 247 - 251
  • [37] MicroRNA-766 inhibits the malignant biological behaviours of pancreatic ductal adenocarcinoma by directly targeting ETS1
    Li, Shiquan
    Yan, Guoqiang
    Yue, Meng
    Kang, Zhenhua
    Wang, Lei
    MOLECULAR MEDICINE REPORTS, 2019, 19 (02) : 1380 - 1387
  • [38] Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
    Pervin, Jannat
    Asad, Mohammad
    Cao, Shaolong
    Jang, Gun Ho
    Feizi, Nikta
    Haibe-Kains, Benjamin
    Karasinska, Joanna M.
    O'Kane, Grainne M.
    Gallinger, Steven
    Schaeffer, David F.
    Renouf, Daniel J.
    Zogopoulos, George
    Bathe, Oliver F.
    FRONTIERS IN GENETICS, 2023, 14
  • [39] The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma
    Ren, Le
    Yu, Yue
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 179 - 187
  • [40] Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma
    Hu, Dingyuan
    Ansari, Daniel
    Zhou, Qimin
    Sasor, Agata
    Hilmersson, Katarzyna Said
    Andersson, Roland
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2019, 17 (1)